OXFORD, UK – 16 December, 2025 – Pathios, in collaboration with Weatherden, was recently featured in Cancers 2026 with a review examining the role of GPR65 in renal cell carcinoma (RCC). The review highlights compelling characteristics of RCC that support our novel mode of action, focusing on the tumor’s particularly acidic environment and its impact on immune suppression and tumor progression through GPR65. The article is bolstered with preclinical data from Pathios GPR65 inhibitors in translational assays, including human primary tumor histocultures.
This publication reflects the strong collaboration between the Pathios and Weatherden teams. We extend special congratulations to our VP of Biology, Barbara Cipriani, and Dr. Michael Grant of Weatherden for their leadership in this valuable work, which underscores the potential of targeting this pathway in RCC and other solid tumors. We also acknowledge the contribution of our academic collaborators: Prof. Michael Millward (The University of Western Australia), Prof. Sumanta Pal, MD, FASCO (City of Hope), and Prof. Ignacio Melero (University of Navarra).
The momentum of the lead asset is built on a foundation of an extensive repository of pre-clinical data highlighting the untapped potential of GPR65 antagonism as a route to life-changing treatments for people with cancer. Read the full publication to learn more about our mechanism and pioneer approach here:
Low pH, High Stakes: A Narrative Review Exploring the Acid-Sensing GPR65 Pathway as a Novel Approach in Renal Cell Carcinoma